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ABSTRACT  
Objective: 22q11.2 deletion syndrome (22q11.2DS) is associated with a >20 fold increased risk  
for developing schizophrenia. The aim of this study was to identify additional genetic factors  
(i.e., ìsecond hitsî) that may contribute to schizophrenia expression. Methods: Through an  
international consortium we obtained DNA samples from 329 psychiatrically phenotyped  
subjects with 22q11.2DS. Using a high resolution microarray platform and established methods  
to assess copy number variation (CNV), we compared the genome wide burden of rare  
autosomal CNV, outside of the 22q11.2 deletion region, between two groups: with and, at age  
³25 years, without a psychotic disorder. We assessed whether genes overlapped by rare CNVs  
were over represented in functional pathways relevant to schizophrenia. Results: Rare CNVs  
overlapping one or more protein coding genes revealed significant between group differences.  
For rare exonic duplications, six of 19 gene sets tested were enriched in the schizophrenia group;  
genes associated with abnormal nervous system phenotypes remained significant in a step wise  
logistic regression model (p=0.00062) and showed significant interactions with 22q11.2 deletion  
region genes in a connectivity analysis. For rare exonic deletions, the schizophrenia group had on  
average more genes overlapped (p=0.0058). The additional rare CNVs implicated known (e.g.,  
GRM7, 15q13.3, 16p12.2) and novel schizophrenia risk genes and loci. Conclusions: The results  
suggest that additional rare CNVs overlapping genes outside of the 22q11.2 deletion region  
contribute  to  schizophrenia  risk  in 22q11.2DS,  supporting  a  multigenic  hypothesis  for  
schizophrenia. The findings have implications for understanding expression of psychotic illness, and 
herald the importance of whole genome sequencing to appreciate the overall genomic 
architecture of schizophrenia.  
  
 
 
INTRODUCTION  
Chromosomal microarray analysis has made routine the ability to detect pathogenic copy number  
variations (CNVs), including recurrent CNVs associated with established genomic disorders.  
Most testing is done postnatally in children with autism spectrum disorder, developmental  
delay/intellectual disability, and/or multiple congenital anomalies, or prenatally (1). Several  
commercial laboratories are now providing the means for non invasive prenatal screening of  
microdeletion  syndromes (2).  With  increased  early  diagnosis,  attention  is  shifting  to  
understanding the later onset expression of genomic disorders.  
 
Of concern is the association of several genomic disorders with schizophrenia (3 5), a serious  
psychotic disorder that typically has onset in adolescence or early adulthood and requires  
lifelong treatment. The recurrent 22q11.2 deletion associated with 22q11.2 deletion syndrome  
(22q11.2DS) has an estimated prevalence of 1 in 3 4,000 live births and, in addition to risk for  
several congenital (e.g., cardiac) anomalies, represents one of the strongest known risk factors  
for  schizophrenia (6).  Schizophrenia  occurs  in  about 1  in 4  patients  with 22q11.2DS,  
representing a >20 fold increase over the general population risk of 1% (6, 7). Given the high but 
incomplete penetrance of the 22q11.2 deletion for schizophrenia, there is considerable interest in 
identifying  additional  genetic  factors  that  may  increase  the  likel ihood  of  an  individual 
developing this illness (6, 8 11).  
Multinational collaborative recruitment efforts can facilitate appropriately powered research of  
individually rare CNVs like 22q11.2 deletions. A goal of the International 22q11.2DS Brain and  
Behavior Consortium (IBBC) (12) is to discover additional genetic factors that contribute to the  
 
 
high risk for schizophrenia in the  22q11.2DS population. Emerging research suggests that  
additional rare CNVs elsewhere in the genome may shape the expression of cardiac phenotypes  
associated with 22q11.2DS (13). In the current study, we used high resolution genome wide  
microarrays and proven CNV detection methods (14) to identify rare CNVs that may be involved  
in the expression of schizophrenia in 22q11.2DS. We chose this strategy given the relatively high  
penetrance (i.e., OR 2 60) of rare genic CNVs for idiopathic schizophrenia (15). This is in  
contrast to common variants, e.g., single nucleotide polymorphisms (SNPs) that are mostly  
located in non coding regions and individually associated with small risks for schizophrenia  
(15). Data from the IBBC 22q11.2DS cohort enabled us to compare genome wide burden and  
genic content of rare autosomal CNVs, outside of the 22q11.2 deletion region, between  
individuals with schizophrenia or related psychotic disorders and those with no psychotic 
disorder at age ³25 years.  
 
 
SUBJECTS AND METHODS  
 
Ascertainment of samples from 22q11.2DS subjects for CNV analysis  
Subjects with a presumed 22q11.2 deletion were recruited from 22 international sites (Table S1) and 
provided DNA samples that were genotyped using the Affymetrix Genome Wide Human SNP 
Array 6.0 at the Albert Einstein College of Medicine (13). Informed consent was obtained from all 
subjects and/or their legal guardian. This study was approved by the local institutional research 
ethics boards of each site.  
 
 
Quality control (QC) measures, ancestry and relatedness determination  
 
 
Similar  to  our  previous  studies  of  CNV  (14),  all  downstream  processing  and  analysis  
of microarray  data,  including  applying  rigorous  methods  for  QC  and  CNV  detection,  
were completed at The Centre for Applied Genomics (TCAG) in Toronto, Canada. Initially,  
there were 866  DNA  samples  available  from  subjects  with  a  presumed 22q11.2  
deletion  and psychiatric phenotype data. Of these,  741 (85.6%) samples had high quality  
CNV data after accounting for batch effects and applying other QC measures (see Supplemental 
Material for full details).  
 
 
Phenotype and diagnostic group determination  
 
Of the 666 unrelated 22q11.2DS subjects of European ancestry with genome wide CNV data,  
n=329 met inclusion criteria for this study. The phenotypic and diagnostic assessment protocol is  
described elsewhere (12). We first selected subjects who met DSM IV TR diagnostic criteria for  
a major psychotic disorder; n=15 subjects with an affective psychosis were excluded. The  
resulting 158 individuals formed the ìschizophrenia groupî, and had specific diagnoses of  
schizophrenia (n=117; 74.1%), schizoaffective disorder (n=12; 7.6%), psychosis not otherwise  
specified (n=20; 12.7%), or schizophreniform (n=1; 0.6%), delusional (n=2; 1.3%), brief  
psychotic (n=2; 1.3%) or other psychotic (n=4; 2.5%) disorders. Median age at onset of  
psychotic illness was 21 (range 7 9) years, with no overall sex difference. We assigned  
individuals to the ìnon psychotic groupî (n=171) if they had no history of any psychotic illness  
when assessed at age ³25 years (median age 32, range 25 67, years). As expected for  
22q11.2DS, given the known impact of ascertainment and disease factors (6), in the non  
psychotic group compared to the schizophrenia group the proportion of female subjects was  
higher (n=113, 66.1% vs n=82, 51.9%, respectively; p=0.0089), the proportion of cases with a  
congenital cardiac defect where known (n=248) was higher [n=74, 58.3% vs n=49, 40.5%, 
respectively; p=0.0051), and the median IQ was higher [75, range 34 105 (n=137) vs 69, range 3694 
(n=121), respectively; p<0.0001].  
 
 
CNV detection and annotation  
Similar to previous studies (14), we used CNV methods that ensure high (>90%) validation using  
a second laboratory method (16) (Table S2). Genome wide CNVs were identified with a  
multiple algorithm approach using Birdsuite (17), iPattern (18), and Affymetrix Genotyping  
Console (http://www.affymetrix.com/) to maximize CNV call accuracy. We included CNVs for  
analyses only if: (i) identified by two or three of the CNV calling algorithms, (ii) spanning 10  
consecutive array probes for deletions or duplications, and (iii) <75% overlap with sequence  
from segmental duplications. We used 9,611 independent population based controls of European  
ancestry  (Table S2) to adjudicate CNV rarity, designating CNVs found in  <0.1% of the  
population controls as ìrareî in the 22q11.2DS subjects. CNVs were adjudicated for microRNA 
(miRNA) content using miRBase (19), and for genic content using RefSeq. CNVs were deemed 
exonic if they overlapped at least one base pair (bp) of coding sequence.  
 
 
CNV burden analysis and statistical approach  
For CNV burden analyses, we compared the proportion of subjects with one or more rare 
autosomal CNVs ³10 kb (all, deletions, duplications, and restricting to those overlapping a gene, exon 
or miRNA) between the schizophrenia and non psychotic groups. Fisherís exact tests, odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated using SAS or R 3.3.1 software. All tests 
were two sided with p<0.05 defined for statistical significance.  
 
 
 
 
Gene-set enrichment analysis  
To assess whether genes overlapped by rare CNVs in the schizophrenia group were over  
represented in functional pathways related to schizophrenia, we evaluated 19 gene sets  
(Table S3) similar to those used in a recent schizophrenia consortium (PGC) study (16).  
These comprised genes with roles in human neurodevelopment, neuronal function, or synaptic 
function (7 sets), or human orthologs of mouse genes whose disruptions cause neurobehavioral or 
nervous system abnormalities (3 sets). Given evidence for miRNA mechanisms in  
schizophrenia and the role of DGCR8 in genome wide miRNA buffering (9, 20), we also  
examined genes predicted to be targets of miRNAs showing differential gene expression with 
haploinsufficiency of DGCR8 in a mouse model (1 set) (9, 10, 20). Eight further gene sets 
involved genes associated with abnormal phenotypes in non brain organ systems (7 sets), or 
causing prenatal or perinatal lethality (1 set), in mice (16).  
The gene set burden analysis used a logistic regression deviance test (21) [R/Bioconductor  
package cnvGSA: Gene Set Analysis of (Rare) Copy Number Variants (version 1.18.0)]  
(https://www.bioconductor.org/packages/release/bioc/html/cnvGSA.html) to evaluate if the  
number of genes overlapped by rare exonic deletions or duplications in each subject for each  
gene set (i.e., gene set specific genic burden) is predictive of the subject being a member of the  
schizophrenia or non psychotic group. We report the regression coefficients after standardizing  
the gene set gene count. Sex was used as a covariate. Similar to our previous whole genome  
sequencing study of 22q11.2DS (9), we also performed a secondary gene set burden analysis that  
included each original gene set after restricting to just the genes that are predicted to be targets of  
DGCR8 (9). Multiple testing correction (Benjamini Hochberg False Discovery Rate, BH FDR)  
was performed separately for each gene set group (with and without DGCR8 restriction) and  
CNV type (deletions, duplications). Gene sets with a BH FDR <10% and p value <0.05 were  
considered to be significantly enriched (9). To account for overlap between the gene sets we re  
tested the burden following a step wise logistic regression approach that used the same  
regression deviance test and covariates after ranking the gene sets based on most to least  
significant p values.  
 
 
Network connectivity test and network construction  
We performed an absolute connectivity test by treating the 46 protein coding genes (n=42  
with network data) in the 22q11.2 deletion region genes as "bait" and the 41 genes from the  
mouse abnormal nervous system gene set overlapped by duplications in the  
22q11.2DS schizophrenia group (n=39 with network data) as "prey". For each bait gene, the  
top 200 interaction neighbors (prey) were retrieved using GeneMANIA physical  
protein protein interaction and pathway interaction networks (22). Since each of the networks  
contains different information, they require weighting based on their capability to predict gene  
functions as defined by Gene Ontology (GO) (22). Accordingly, we used the weighting  
procedure implemented in GeneMania and selected GO Biological Process functional  
annotations to pre weight the selected protein interaction networks (22), as more  
representative of pathways than GO Cellular Component and Molecular Function. We  
determined a connectivity score for each bait gene using the average of the respective  
preysí GeneMANIA scores  and performed  an empirical test to compare this  
connectivity score to that for the 15,824 genes outside the 22q11.2 deletion region. Nominal  
p values were then corrected using Benjamini Hochberg FDR. We generated a gene  
interaction  
proximity network using the results from the network connectivity analysis, and ìlinkerî genes 
identified using GeneMANIA (22), visualizing the resulting network in Cytoscape (23).  
 
 
RESULTS  
22q11.2 deletions  
 
There was no significant between group difference in the distribution of 22q11.2 deletions  
(c2=0.18, df=1, p=0.68). The majority of subje ts had LCR A D 22q11.2 deletion (s hizophrenia 
n=147, 93.0%; non psy hoti  n=157, 91.8%; Figure S1), three subje ts (1.9%) in the  
s hizophrenia group had a known proximal variant of the LCR A D deletion and the remainder had 
a LCR A B (s hizophrenia n=7, 4.4%; non psy hoti  n=11, 6.4%) or LCR A C  
(s hizophrenia n=1, 0.6%; non psy hoti  n=3, 1.8%) deletion (Figure S1).  
 
 
Quantitative genome-wide burden of additional rare CNVs  
In the overall sample of 329 subje ts with a 22q11.2 deletion, there were 726 additional rare 
genome wide autosomal CNVs in 291 (88.4%) subje ts (s hizophrenia n=142, 89.9%; non psy 
hoti  n=149, 87.1%; Table S4, S5). The proportion of s hizophrenia subje ts (n=16, 10.1%) with one 
or more rare CNVs overlapping a miRNA was non signifi antly greater than that of the non psy hoti  
group (n=8, 4.7%; p=0.0878).  
There were 272 rare CNVs (173 dupli ations, 99 deletions) that overlapped at least 1 bp of  
oding sequen e in 182 (55.3%) subje ts. Those with exoni  dupli ations (s hizophrenia n=68,  
43.0%; non psy hoti  n=59, 34.5%) outnumbered those with exoni  deletions (s h izophrenia  
n=38, 24.1%; non psy hoti  n=47, 27.5%) in both subje t groups. There were no overall  
 
 
between group  differen es  in  the  total  number  of  rare  CNVs  (deletions  and/or  
dupli ations, Table S4), or in the total genomi  length of rare CNVs per subje t (median: 173 kb, 
range: 12 kb 3.6 Mb, vs median: 184 kb, range: 11 kbñ1.9 Mb for schizophrenia and non 
psychotic groups, respectively; p=0.48). Restricting to rare exonic CNVs showed similar results 
(data not shown).  
However, when examining the total number of genes (regardless of function) overlapped by  
the additional rare CNVs, there were significantly more genes overlapped by rare exonic  
deletions in the  schizophrenia  group (median: 2  genes,  range: 1 18)  compared  to  the  
non psychotic group (median: 1 gene, range: 1 14; p=0.0058) (Table 1). There was no such 
significant finding for duplications. There was no significant difference in the IQ scores of 
individuals with and without an additional rare exonic deletion in either the schizophrenia or non 
psychotic groups (data not shown). Multigenic rare deletions in the schizophrenia group 
included a 410 kb 1q21.1 deletion (at the TAR locus) and a 600 kb 16p12.2 deletion, both 
previously associated with schizophrenia in general population samples (3).  
 
 
Functional burden of additional rare CNVs  
We performed a gene set enrichment analysis in order to identify between group differences  
in the burden of rare CNVs overlapping functionally related genes (i.e., gene sets or  
pathways). Compared to the non psychotic group, after multiple test correction (BH FDR<10%  
and nominal p value <0.05), the schizophrenia group had significantly more individuals  
with rare exonic duplications overlapping genes from six of the 19 gene sets assessed (Table  
2).   There were no between group differences for deletions. Of the six significantly enriched gene 
sets, only the top  
ranking Nervous System Phenotype gene set remained significant (p=0.00062) in the stepwise 
logistic regression model (Table 2); overlap of the gene signal with the other five gene sets is 
shown in Table S6. Secondary gene set analyses, restricting to genes predicted to be affected by 
DGCR8 haploinsufficiency (9, 20), showed significant improvement in the burden analysis 
results  over  that  for  the  full  gene set  only  for  the  Muscle/Cardiovascular  gene set, after 
permutation to account for gene set size (data not shown).  
In 32 subjects with 22q11.2DS schizophrenia, there were 37 rare duplications that contributed to  
the Nervous System Phenotype gene set result (Tables 2, 3). For individuals with IQ data  
available, there was no significant difference in the median IQ between those with (n=23) and  
without (n=104) a rare duplication contributing to this gene set result (68 vs. 70, p=0.41). Four  
(10.8%)  duplications  were  recurrent,  flanked  by  segmental  duplications,  and  previously  
associated  with  idiopathic  schizophrenia (Table 3).  These  included  two 22q11.2DS  
schizophrenia subjects with 1.9 2.0 Mb duplications at 15q13.2 q13.3 (BP4 BP5) (24), one with  
a 1.5 Mb duplication at 17q12 (25), and one with a 1.3 Mb duplication at 22q11.23 (26).  
Eighteen (48.6%)  of  the 37  CNVs  overlapped  a  single  gene,  including  several  genes  
implicated in idiopathic schizophrenia by rare variant studies, such as RYR2 (3, 21), GRM7 (3, 27), 
DOK7 (3, 28), and CACNA2D1 (3, 29). In silico breakpoint analysis indicated that the majority 
(n=28; 65.1%) of the genes implicated in the rare duplication gene set results had coding 
sequence that was disrupted by the CNV (data not shown).  
 
 
Potential mechanisms of rare CNV-related risk for schizophrenia in 22q11.2DS  
We attempted to identify potential mechanisms contributing to the schizophrenia risk posed by  
the additional rare duplications overlapping genes from the Nervous System Phenotype gene set  
(Tables 3).  Using  protein protein  interaction  data  available  from  GeneMANIA (22),  we  
empirically tested whether genes in the 22q11.2 region (n=46 total,  42 with network data) were 
more connected to the Nervous System Phenotype genes overlapped by rare duplications in the 
schizophrenia group (n=41 total, 39 with network data), when compared to 15,824 other protein 
coding genes in the genome. This analysis revealed four 22q11.2 deletion region genes with 
significant interactions at FDR<20% (nominal p value <0.02): P2RX6, SEPT5, RTN4R and 
CLTCL1 (Table S7; Figure 1). The a priori probability of randomly extracting 42 genes from the 
genome with at least four genes achieving significant connectivity at FDR<20% is <0.0098, 
providing further support for this result.  
The interaction proximity network constructed using the four 22q11.2 deletion region genes and  
the genes implicated by the duplication gene set findings suggested a diverse set of pathways  
potentially related to schizophrenia pathogenesis (Figure 1). Four interaction clusters were  
characterized by the presence of a significant gene from the 22q11.2 deletion region and/or at  
least one schizophrenia only  gain  gene: axon guidance and neuronal adhesion (UNC5D,  
DSCAM), axon guidance and nerve growth factor signalling (RTN4R; TNFRSF19), purinergic  
receptors  and  calcium  channels (P2RX6;  CACNA2D1),  and  glutamatergic  and  adenosine  
receptors, synaptic trafficking (CLTCL1; ADORA2A, GRM7) (Figure 1).  
 
 
DISCUSSION  
The results of the current study provide new data relevant to a key knowledge gap in our  
understanding of the association between genomic disorders like 22q11.2DS, and a profoundly  
increased risk for developing major psychotic illnesses such as schizophrenia. For the first time,  
there are sufficient data to support additional rare CNVs that overlap protein coding sequence as  
contributing factors to this increased risk. These comprise both rare duplications that overlap  
genes involved in neuronal function and rare loss CNVs that tend to overlap more genes in those  
who develop schizophrenia. The findings suggest the possibility that additional information  
captured by chromosomal microarray at the time of initial diagnosis of a 22q11.2 deletion could  
eventually help in identifying some of those at greatest risk for schizophrenia.  
 
The results are consistent with emerging research suggesting that rare deleterious variants  
elsewhere in the genome, in addition to the 22q11.2 deletion, are likely to be involved in the  
variability  of  neuropsychiatric  and  other  developmental  expression  of  this  microdeletion  
syndrome (6, 8 11). This finding has potential implications for the schizophrenia risk associated  
with other genomic disorders, such as the 3q29 deletion (30) or 16p11.2 duplication (31). The  
results  are  also  in  keeping  with data  from the  general  population  of  individuals  with  
neurodevelopmental disorders, where ~4% have two rare  contributing genetic mutations or  
genetic diagnoses (32). Although there are case reports of two rare CNVs in patients with  
schizophrenia (33, 34), there are few previous studies of genome wide CNVs in patients with  
typical 22q11.2 deletions, and these involved small samples and/or used low resolution arrays or  
various methods to assess CNVs and their rarity (8, 33 3 ). Only two of these small studies  
compared schizophrenia and non psychotic groups within 22q11.2DS (8, 35).  
  
   
The results of this study are in line with findings supporting an association between large,  
usually multigenic, rare duplications and schizophrenia in the general population (5, 14).  
Similarly, the results for enriched burden of genes overlapped by rare deletions in 22q11.2DS  
schizophrenia also appear consistent with studies of schizophrenia in the general population (16),  
and with a recent rare CNV study reporting a higher number of overlapped genes in a large  
schizophrenia cohort compared with controls (36). Within 22q11.2DS, the structural variant  
results in the current study complement those of pilot whole genome sequencing findings for  
22q11.2DS  using  an  extreme  phenotype  approach  to  study  additional  genome wide  rare  
sequence variants affecting schizophrenia expression (9). In that pilot study there was a  
significantly enriched burden of high quality non synonymous deleterious missense and loss of  
function sequence variants brain related genes in the schizophrenia cases (9). Genes involved  
included RYR2 (3, 37) and BSN (38), the latter encoding a pre synaptic scaffolding protein,  
bassoon (9). Results of the current study (Table 3) further implicate these more novel genes and  
pathways for schizophrenia. The RYR2 gene and two genes (DLC1 and ABCA4) encoding  
members  of  a  BSN  superfamily  of  neuronal  transmembrane  proteins  that  regulate  
neurotransmitter release at the synapse were overlapped by very rare duplications in subjects  
with 22q11.2DS and schizophrenia. BSN was also implicated in the synaptic network derived  
from a large CNV study of schizophrenia (16), as were some of the network connections in the  
current study (Figure 1).  
 
The significant genetic interactions between 22q11.2 deletion region genes and duplication locus  
genes implicate other pathways of potential interest to schizophrenia pathogenesis. These include  
the RTN4R gene encoding the Nogo receptor and its co receptor, TNFRSF19, involved in  
  
mediating axonal growth inhibition, regeneration and plasticity, and limiting excitatory synapse  
number during brain development (39). Similarly, the P2RX6 related functional gene cluster  
includes  RYR2  and  CHRNA7  and  CACNA1C,  previously  implicated  in  schizophrenia  
pathogenesis (40). Several of the genes in the network (Figure 1) have also been implicated as  
targets of 22q11.2 region miRNAs or of miRNAs dysregulated by DGCR8 haploinsufficiency  
(10). Interestingly, there is also some evidence from a recent brain expression study implicating 
RTN4R and P2RX6 down regulation in the pathogenesis of idiopathic schizophrenia (41), further 
supporting the potential generalizability of the findings in the current study.  
The 22q11.2 deletion may lower the threshold for expression of the multiple mechanisms and/or  
pathways involved in causing schizophrenia, within and between individuals (9, 10). The results  
of the current study primarily implicate additional genome wide rare CNVs that affect protein  
coding sequence of genes in the expression of schizophrenia in the context of a 22q11.2 deletion.  
Effect sizes may be smaller for other mechanisms. For example, non coding regulatory regions  
and/or miRNAs (at the trend level in this study) may also play important roles in schizophrenia,  
including  in 22q11.2DS,  as  suggested  by  rare  sequence  variant  findings  for 22q11.2DS  
supporting DGCR8 haploinsufficiency and altered miRNA buffering mechanisms (9, 20). Power  
may also be an issue for the difference observed in additional rare CNV findings in 22q11.2DS  
between those for duplications and deletions. A more neuro specific effect for deletions could  
perhaps become apparent if the sample size were larger. However, mechanisms for expression of  
deletions and duplications may differ (1), and penetrance is, on average, higher for deletions than  
duplications (33). In the presence of the 22q11.2 deletion, additional rare deletions may be more  
likely to potentially implicate pleiotropic genes in expression of schizophrenia, whereas  
 duplications  could  require  genes  having  greater  specific  impact  on  neuronal  functioning.  
Notably,  the  rare  duplication  burden  in 22q11.2DS schizohrenia  was  enriched  for  genes  
associated with mouse neurobehavioral phenotypes, similar to results in a recent large case  
control study of schizophrenia, though the latter involved somewhat smaller effect sizes (OR  
1.18, 1.68, respectively) and deletions, including most commonly the 22q11.2 deletion (16). 
Results from the current study provide some evidence for the expression of schizophrenia in 
22q11.2DS involving network interactions that include genes in the 22q11.2 deletion region and 
genes overlapped by other rare structural variants outside this locus.  
 
 
Advantages and limitations  
Despite having the largest sample of 22q11.2DS subjects with and without a psychotic disorder  
to study the impact of additional rare CNVs on expression, power was limited by the available  
cohort size. However, the signal related to schizophrenia expression imparted by additional rare  
genome wide CNVs produced significant results. This is remarkable, given the virtually  
ubiquitous  presence  of  any  neurodevelopmental  phenotype  in 22q11.2DS (42),  and  the  
likelihood that some subjects in the non psychotic group may go on to develop schizophrenia. It  
is expected that some of the rare CNVs associated with schizophrenia and the genes implicated  
may also be involved in expression of other neurodevelopmental disorders, consistent with the  
literature supporting overlap of pathways (15).  However, the results do not support intellect as a  
primary driver of the findings, and while most subjects were not systematically assessed for the  
presence of autism spectrum disorder, this was documented for a few subjects (n=18; 5.5%). The  
ability to recruit more adults with no psychotic illness and individuals with schizophrenia within  
the 22q11.2DS population could provide the means to identify the strength of the relationship  
between each additional CNV and the risk for schizophrenia, as well as other mechanisms for 
schizophrenia expression where the effect sizes are lower. In future studies, larger samples of 
22q11.2DS may also assist in determining the role of X chromosome variants and whether, as in 
autism and ID (43), the X chromosome may provide some protective capacity for schizophrenia 
expression in the context of a 22q11.2 deletion.  
The IBBC proband only 22q11.2DS sample provides no capability of examining inheritance, 
parent of origin, or segregation data for the 22q11.2 deletion or the additional CNVs, or the 
family history of schizophrenia, all of which are factors of interest in disease expression (11). In 
smaller samples, the parental origin and inheritance status of the 22q11.2 deletion have not 
appeared to play a role in schizophrenia expression, however (8), and one can expect that >90% of 
the 22q11.2 deletions would be de novo mutations (6).  
 
 
Conclusions  
The results suggest that additional rare CNVs overlapping genes outside of the 22q11.2 deletion  
region contribute to schizophrenia risk in 22q11.2DS. The fact that these results involved fewer  
than half of the subjects with schizophrenia supports the likelihood that other yet to be identified  
variants and mechanisms also play a role in expression. The recurrent 22q11.2 deletion is known  
to occur as a de novo event in >90% of cases and at any parental age (6, 8), but the inheritance of  
additional genome wide CNVs remains to be determined. The findings support a multigenic  
hypothesis for schizophrenia, and further illustrate the value of a 22q11.2DS model for  
identifying genome wide rare variants to help delineate the genetic architecture of idiopathic  
schizophrenia. Lessons learned from 22q11.2DS may be applicable to other recurrent CNVs that  
contribute to risk for schizophrenia in the general population (14). Whole genome sequencing will 
allow for more detailed assessment of CNV breakpoints, and the overall genetic architecture and 
proposed mechanisms of schizophrenia (9, 20).  
  
 
 
FIGURE LEGEND  
Figure 1: Gene interaction proximity network based on physical and pathway interactions  
Circles correspond to genes: 22q11.2 deletion genes with significant connectivity (CLTCL1,  
P2RX6, RTN4R, and SEPT5, purple), genes with mouse abnormal nervous system phenotypes  
overlapped by duplications exclusively in the 22q11.2DS schizophrenia group (red), and linker  
genes (gold). The initial sets comprised the four 22q11.2 deletion region genes with significant  
connectivity and the 39 genes overlapped by duplications found exclusively in schizophrenia  
subjects and within the nervous system phenotype gene set. Important ìlinkerî genes were  
identified by retrieving the top 25 interaction neighbours of these genes in GeneMANIA, using  
the same protein protein interaction and pathway interaction networks used in the connectivity  
test, and then sub setting to those found connected to at least two different bait genes and  
belonging to the nervous system phenotype gene set (86 genes). Connections correspond to  
interaction proximity obtained from GeneMANIA, setting the limit to the top 50 interactors; the  
connection line thickness is proportional to the GeneMANIA score (22). The resulting network is  
visualized in Cytoscape (23).  The network suggests the presence of  four interaction clusters,  
characterized by the presence of one gene from the 22q11.2 deletion region with significant  
connectivity results and at least one schizophrenia only duplication related gene (see text for  
details).  
  
 
 
REFERENCES  
 
1. Miller DT, Adam MP, Aradhya S, et al: Consensus statement: chromosomal microarray is a 
first tier clinical diagnostic test for individuals with developmental disabilities or congenital 
anomalies. Am J Hum Genet. 2010; 86:749 764  
2. Gross SJ, Stosic M, McDonald McGinn DM, et al: Clinical experience with  
single nucleotide polymorphism based non invasive prenatal screening for 22q11.2 deletion 
syndrome. Ultrasound Obstet Gynecol. 2016; 47:177 183  
3. Costain G, McDonald McGinn D, Bassett A Prenatal genetic testing with chromosomal 
microarray analysis identifies major risk variants for schizophrenia and other later onset 
disorders. Am J Psychiat. 2013; 170:1498  
4. Lowther C, Costain G, Stavropoulos DJ, et al: Delineating the 15q13.3 microdeletion  
phenotype: a case series and comprehensive review of the literature. Genet Med. 2014;  
5.Isles AR, Ingason A, Lowther C, et al: Parental Origin of Interstitial Duplications at  
15q11.2 q13.3 in Schizophrenia and Neurodevelopmental Disorders. PLoS Genet. 2016; 
12:e1005993  
6. McDonald McGinn DM, Sullivan KE, Marino B, et al: 22q11.2 deletion syndrome. Nat Rev Dis 
Prim. 2015:15071  
7. Fung WL, McEvilly R, Fong J, et al: Elevated prevalence of generalized anxiety disorder in 
adults with 22q11.2 deletion syndrome. Am J Psychiatry. 2010; 167:998  
8. Bassett AS, Marshall CR, Lionel AC, et al: Copy number variations and risk for  
schizophrenia in 22q11.2 deletion syndrome. Hum Mol Genet. 2008; 17:4045 40 3  
9. Merico D, Zarrei M, Costain G, et al: Whole genome sequencing suggests schizophrenia risk 
mechanisms in humans with 22q11.2 deletion syndrome. G3 (Bethesda). 2015;  
 
 
10. Merico D, Costain G, Butcher NJ, et al: MicroRNA dysregulation, gene networks, and risk  
for schizophrenia in 22q11.2 deletion syndrome. Front Neurol. 2014; 5:238  
11. Klaassen P, Duijff S, Swanenburg de Veye H, et al: Explaining the variable penetrance of 
CNVs: Parental intelligence modulates expression of intellectual impairment caused by the 
22q11.2 deletion. Am J Med Genet B Neuropsychiatr Genet. 2016; 171:790 796  
12. Schneider M, DebbanÈ M, Bassett AS, et al: Psychiatric disorders from childhood to  
adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain an d 
Behavior in 22q11.2 Deletion Syndrome. Am J Psychiat. 2014; 171:627 639  
13. Mlynarski EE, Xie M, Taylor D, et al: Rare copy number variants and congenital heart 
defects in the 22q11.2 deletion syndrome. Hum Genet. 2016; 135:273 285  
14. Costain G, Lionel A, Merico D, et al: Pathogenic rare copy number variants in community 
based schizophrenia suggest a potential role for clinical microarrays. Hum Mol Genet. 2013;  
22:4485 4 01  
15 . Harrison PJ Recent genetic findings in schizophrenia and their therapeutic relevance. J 
Psychopharmacol. 2015; 29:85 96  
16. CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium  
Contribution of copy number variants to schizophrenia from a genome wide study of 41,321 
subjects. Nat Genet. 2017; 49:27 3  
17. Korn JM, Kuruvilla FG, McCarroll SA, et al: Integrated genotype calling and association 
analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet. 2008;  
40:1253 1260  
18. Pinto D, Darvishi K, Shi X, et al: Comprehensive assessment of array based platforms and 
calling algorithms for detection of copy number variants. Nat Biotechnol. 2011; 29:512 20  
19. Kozomara A, Griffiths Jones S miRBase: integrating microRNA annotation and deep 
sequencing data. Nucleic Acids Res. 2011; 39:D152 157  
20. Brzustowicz LM, Bassett AS miRNA mediated risk for schizophrenia in 22q11.2 deletion  
syndrome. Front Genet. 2012; 3:291  
21. Kirov G, Pocklington AJ, Holmans P, et al: De novo CNV analysis implicates specific  
abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol 
Psychiatry. 2012; 17:142 153  
22. Warde Farley D, Donaldson SL, Comes O, et al: The GeneMANIA prediction server: 
biological network integration for gene prioritization and predicting gene function. Nucleic 
Acids Res. 2010; 38:W214 220  
23. Cline MS, Smoot M, Cerami E, et al: Integration of biological networks and gene 
expression data using Cytoscape. Nat Protoc. 2007; 2:2366 2382  
24. Zhou D, Gochman P, Broadnax DD, et al: 15q13.3 duplication in two patients with  
childhood onset schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2016; 171:777 783 25 
. Szatkiewicz JP, O'Dushlaine C, Chen G, et al: Copy number variation in schizophrenia in Sweden. 
Mol Psychiatry. 2014; 19:762 773  
26. Rodriguez Santiago B, Brunet A, Sobrino B, et al: Association of common copy number 
variants at the glutathione S transferase genes and rare novel genomic changes with  
schizophrenia. Mol Psychiatry. 2010; 15:1023 1033  
27. Melhem N, Middleton F, McFadden K, et al: Copy number variants for schizophrenia and 
related psychotic disorders in Oceanic Palau: risk and transmission in extended pedigrees. Biol 
Psychiatry. 2011; 70:1115 1121  
28. Xu B, Roos JL, Levy S, et al: Strong association of de novo copy number mutations with 
sporadic schizophrenia. Nat Genet. 2008; 40:880 885  
29. Purcell SM, Moran JL, Fromer M, et al: A polygenic burden of rare disruptive mutations in 
schizophrenia. Nature. 2014; 506:185 190  
30. Mulle JG, Dodd AF, McGrath JA, et al: Microdeletions of 3q29 confer high risk for 
schizophrenia. Am J Hum Genet. 2010; 87:229 236  
31. McCarthy SE, Makarov V, Kirov G, et al: Microduplications of 16p11.2 are associated with 
schizophrenia. Nat Genet. 2009; 41:1223 1227  
32. Yang Y, Muzny DM, Xia F, et al: Molecular findings among patients referred for clinical 
whole exome sequencing. JAMA. 2014; 312:1870 1879  
33. Kirov G, Rees E, Walters JT, et al: The penetrance of copy number variations for 
schizophrenia and developmental delay. Biol Psychiatry. 2014; 75:378 385  
34. Girirajan S, Rosenfeld JA, Coe BP, et al: Phenotypic heterogeneity of genomic disorders and rare 
copy number variants. N Engl J Med. 2012; 367:1321 1331  
35. Williams HJ, Monks S, Murphy KC, et al: Schizophrenia two hit hypothesis in velo cardio 
facial syndrome. Am J Med Genet B Neuropsychiatr Genet. 2013; 162B:177 182  
36. Ruderfer DM, Hamamsy T, Lek M, et al: Patterns of genic intolerance of rare copy number 
variation in 59,898 human exomes. Nat Genet. 2016; 48:1107 1111  
37. Ambalavanan A, Girard SL, Ahn K, et al: De novo variants in sporadic cases of childhood onset 
schizophrenia. Eur J Hum Genet. 2016; 24:944 948  
38. Kaeser PS, Deng L, Wang Y, et al: RIM proteins tether Ca2+ channels to presynaptic active 
zones via a direct PDZ domain interaction. Cell. 2011; 144:282 295  
39. Wills ZP, Mandel Brehm C, Mardinly AR, et al: The nogo receptor family restricts synapse 
number in the developing hippocampus. Neuron. 2012; 73:466 481  
40. Tarabeux J, Kebir O, Gauthier J, et al: Rare mutations in N methyl D aspartate glutamate  
receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry. 2011; 1:e55  
41. Fromer M, Roussos P, Sieberts SK, et al: Gene expression elucidates functional impact of 
polygenic risk for schizophrenia. Nat Neurosci. 2016; 19:1442 1453  
42. Fung WL, Butcher NJ, Costain G, et al: Practical guidelines for managing adults with 
22q11.2 deletion syndrome. Genet Med. 2015; 17:599 609  
43. Jacquemont S, Coe BP, Hersch M, et al: A higher mutational burden in females supports a  
"female protective model" in neurodevelopmental disorders. Am J Hum Genet. 2014; 94:415  
425  
44. Szafranski P, Schaaf CP, Person RE, et al: Structures and molecular mechanisms for  
common 15q13.3 microduplications involving CHRNA7: benign or pathological? Hum Mutat. 
2010; 31:840 850  
45. Mitchell E, Douglas A, Kjaegaard S, et al: Recurrent duplications of 17q12 associated with 
variable phenotypes. Am J Med Genet A. 2015; 167A:3038 3045  
  
 
 
 
Table 1. Average number of genes overlapped by additional rare exonic autosomal CNVs in 22q11.2DS  
 
 
 
 
Deletion or 
duplication 
Deletionb 
Duplication 
22q11.2DS- 22q11.2DS- 
Schizophrenia Non-Psychotic Analysis 
(n=142)a (n=149)a 
Median Range Median Range Z p 
2 1-26 2 1-26 1.5787 0.1144 
2 1-18 1 1-14 2.7569 0.0058 
2 1-26 2 1-26 0.1470 0.8831  
 
 
 
All rare (0.1%) CNVs >10kb and <6.5Mb were included in the analysis. The 22q11.2 deletion region, sex chromosomes, and CNVs  
overlapping >75% of a segmental duplication were excluded. See Methods for details. aSample sizes represent those 22q11.2DS  
subjects in each group (142/158 (89.9%) schizophrenia; 149/171 (87.1%) non-psychotic) with one or more additional rare CNVs.  
bDeletions that overlapped exons were present in 38 (24.1%) 22q11.2DS subjects with schizophrenia and 47 (27.5%) of those with no  
psychotic illness  
  
 
 
 
Table 2. Gene-sets showing significant enrichment in the 22q11.2DS-schizophrenia group for rare exonic duplications 
 
22q11.2DS- 
Gene-set 
 
 
Name 
Nervous System Phenotype (MGI) 
Neurobehavioural Phenotype (MGI) 
Neural Phenotype Union (MGI) 
Muscle/Cardiovascular Phenotype 
(MGI) 
Endocrine/Exocrine/Reproduction 
Phenotype (MGI) 
GO Synaptic 
22q11.2DS-Schizophrenia 
(n=142)a 
 
Total Number of Subjects 
genes CNVs n % 
2609 37 32 22.5 
2602 37 33 23.2 
3764 48 42 29.6 
2327 27 25 17.6 
 
2298 31 31 21.8 
860 15 14 9.9 
Non-psychotic 
(n=149)a 
Number of Subjects 
CNVs n % 
16 15 10.1 
19 19 12.8 
25 24 16.1 
13 13 8.7 
18 17 11.4 
6 6 4.0 
Analyses 
FDR- 
p OR 
BH 
0.00062 0.012 2.36 
0.00174 0.016 2.21 
0.00260 0.016 1.80 
0.00481 0.022 2.38 
0.01099 0.042 2.08 
0.02472 0.078 2.81  
aSample sizes represent those 22q11.2DS subjects in each group with one or more rare CNV (142/158 (89.9%) schizophrenia, 149/171 
(87.1%) non-psychotic. Rare (0.1%) CNVs >10kb and <6.5Mb; CNVs in the chromosome 22q11.2 region and on the X chromosome 
and/or overlapping a segmental duplication by >75% were a priori excluded from analyses.  
n / %, The number and percent of unrelated 22q11.2DS individuals with schizophrenia or non-psychotic with at least one duplication 
contributing to the gene-set result; p, logistic regression model comparison deviance test p-value; The p value for the Nervous system 
phenotype gene-set represents the gene-set result remaining significant after stepwise model construction (i.e., when gene-sets were 
serially added to an increasingly larger regression model, starting with this gene-set; see Methods for details); FDR-BH: 
BenjaminiHochberg false discovery rate (significance level set at <0.10); OR: Odds ratio, calculated by taking the exponential of the 
regression coefficient value; MGI: Mouse Genome Informatics; GO: Gene Ontology.  
  
 
 
 
Table 3. Genes contributing to Nervous System gene-set rare genome-wide duplication results significantly enriched in the 
22q11.2DS schizophrenia groupa 
 
 
CNV Subject Chr Cytoband 
 
 
1 17 1 1p22.1 
2 130 1 1q32.2 
3 93 1 1q43 
4 144 2 2q35 
5 39 3 3p26.1 
6 55 3 3p22.2 
 
7 28 3 3q29 
 
8 130 4 4p16.3 
9 42 4 4p15.2 
10 65 4 4q35.1 
11 110 6 6q11.1 
12 15 6 6q26 
13 150 6 6q27 
14 141 7 7p21.2 
15 55 7 7q21.11 
16 114 8 8p23.3 
17 127 8 8p22 
18 110 8 8p12 
19b 143 8 8q12.1 
20 79 9 9q22.2 
21 10 10 10q23.31 
22 35 10 10q24.2 
23 15 11 11q13.5 
 
 
Start Size 
 
 
94463617 18760 
209881045 28340 
237492310 26855 
216834680 340811 
7619772 536651 
38608585 510439 
 
195263161 232072 
 
3463452 10187 
26433603 49693 
186979699 76584 
62234532 270027 
161687430 1202784 
168167050 228482 
13946099 33357 
81993260 185718 
427857 77504 
13329776 290648 
34906448 250455 
56722133 159268 
93616404 82699 
89651696 46930 
99411165 39708 
76735763 156340 
 
 
Number 
of genes 
 
1 
1 
1 
5 
1 
4 
 
4 
 
1 
2 
1 
2 
2 
2 
1 
1 
1 
2 
1 
2 
1 
1 
2 
4 
 
 
Very Flanking 
All genes overlapped by CNV 
rare LCR 
CNV 
•  ABCA4 
•  HSD11B1 
•  RYR2 
•  TMEM169,MARCH4,PECR,XRCC5,MREG 
•  GRM7 
•  WDR48,SCN11A,SCN5A,SCN10A 
APOD,MUC4,MUC20,PPP1R2,miR-570- 
5p,miR-570-3p 
•  DOK7 
•  RBPJ,CCKAR 
TLR3 
MTRNR2L9,KHDRBS2 
•  AGPAT4,PARK2 
•  MLLT4,HGC6.3 
•  ETV1 
CACNA2D1 
•  TDRP 
•  DLC1,C8orf48 
•  UNC5D 
LYN,TGS1 
SYK 
•  PTEN 
AVPI1,PI4K2A 
•  B3GNT6,OMP,MYO7A,CAPN5 
Gene(s) contributing to Nervous 
System gene-set results 
ABCA4 
HSD11B1 
RYR2 
XRCC5 
GRM7 
SCN11A,SCN5A,SCN10A 
APOD 
DOK7 
CCKAR 
TLR3 
KHDRBS2 
PARK2 
MLLT4 
ETV1 
CACNA2D1 
TDRP 
DLC1 
UNC5D 
LYN 
SYK 
PTEN 
PI4K2A 
MYO7A,OMP  
 
 
 
 
 
Table 3 continued… 
 
 
 
 
 
 
 
 
 
Number Very 
 
 
 
 
 
 
 
 
 
Gene(s) contributing to Nervous 
CNV Subject Chr 
 
24 86 11 
 
25 12 12 
 
 
26 116 13 
 
27 30 14 
 
 
28c 92 15 
 
 
 
29c 52 15 
 
30 131 15 
31 33 16 
 
 
32b,c 132 17 
 
 
33 147 18 
34 34 20 
35 130 20 
36 41 21 
 
 
37 121 22 
Cytoband 
 
11q23.3 
 
12q24.21,12q24.2  
2 
 
13q12.12 
 
14q32.11 
 
 
15q13.2,15q13.3 
 
 
 
15q13.2,15q13.3 
 
15q25.1 
16q24.3 
 
 
17q12 
 
 
18q23 
20p13 
20p11.21 
21q22.2 
 
 
22q11.23 
Start Size 
 
11501086 
7 139977 
11639611 
1021914 
3 
 
23397621 1690189 
 
91288380 77382 
 
 
30668479 1952748 
 
 
 
30747394 2129590 
 
78421669 15345 
89420230 258822 
 
 
34816256 1428102 
 
 
74711326 80540 
4895803 181274 
25061344 198784 
41337036 120608 
 
 
23675258 1384582 
of genes 
 
1 
 
6 
 
 
9 
 
1 
 
 
9 
 
 
 
9 
 
1 
4 
 
 
15 
 
 
1 
1 
3 
1 
 
 
26 
rare Flanking All genes overlapped by CNV 
CNVs LCR 
• 
CADM1 
•  FBXW8,MAP1LC3B2,MED13L,RNFT2,C12or 
f49,HRK,miR-4472,miR-620 
•  SPATA13,C1QTNF9,C1QTNF9B,SGCG,C1Q, 
TNF9B-AS1 ,PARP4, MIPEP, SACS, 
TNFRSF19, miR-2276-5p,miR-2276-3p 
•  RPS6KA5 
•  KLF13,OTUD7A,MTMR10,FAN1,CHRNA7,L 
OC283710,ARHGAP11B,TRPM1,CHRFAM7 
A,miR-211-5p,miR-211-3p 
•  KLF13,OTUD7A,MTMR10,FAN1,GOLGA8O, 
CHRNA7,LOC283710,ARHGAP11B,TRPM1, 
miR-211-5p,miR-211-3p 
•  CIB2 
•  RPL13,SPG7,CPNE7,ANKRD11 
•  ZNHIT3,LHX1,DUSP14,MRM1,ACACA,DD 
X52,DHRS11,SYNRG,C17orf78,HNF1B,AAT 
F,MYO19,PIGW,TADA2A,GGNBP2,miR- 
378j,miR-2909 
•  MBP 
•  SLC23A2 
•  ENTPD6,PYGB,VSX1 
•  DSCAM 
•  SMARCB1,MMP11,C22orf43,DDTL,RGL4,SL 
C2A11,MIF,CHCHD10,DERL3,C22orf15,IGL 
L1,GSTT2B,ZNF70,DDT,VPREB3,GSTT2,AD 
ORA2A,SNRPD3,FAM211B,CABIN1,SPECC 
1L,GUCD1,SUSD2,GGT5,UPB1,GGT1 
System gene-set results 
CADM1 
FBXW8 
C1QTNF9B,TNFRSF19 
RPS6KA5 
CHRNA7,TRPM1 
CHRNA7,TRPM1 
CIB2 
SPG7 
LHX1 
MBP 
SLC23A2 
VSX1 
DSCAM 
ADORA2A,MIF,SMARCB1  
a  Results for the 22q11/2DS-non-psychotic group appear in Table S5.  
b  
CNVs 19 and 32 overlapped with CNVs also found in 22q11.2DS-Non-psychotic subjects (Table S5); cCNVs 28 and 29, and CNV 32, are recurrent CNVs of  
uncertain pathogenicity (44, 45); LCR, low-copy repeats.  
  
   
 
